Dynamic Technology Lab Private Ltd raised its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 110.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,471 shares of the life sciences company's stock after purchasing an additional 3,924 shares during the period. Dynamic Technology Lab Private Ltd's holdings in Illumina were worth $998,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also added to or reduced their stakes in ILMN. Bleakley Financial Group LLC bought a new position in shares of Illumina during the 4th quarter worth approximately $751,000. Zacks Investment Management acquired a new position in shares of Illumina during the third quarter worth $2,924,000. Van ECK Associates Corp lifted its holdings in shares of Illumina by 17.5% during the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company's stock valued at $20,347,000 after purchasing an additional 22,718 shares during the last quarter. Strategic Financial Concepts LLC acquired a new stake in shares of Illumina in the 4th quarter worth $1,464,000. Finally, Allworth Financial LP grew its stake in Illumina by 720.7% during the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company's stock worth $1,001,000 after buying an additional 6,263 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several equities analysts recently commented on ILMN shares. HSBC lowered shares of Illumina from a "buy" rating to a "hold" rating and set a $100.00 price objective for the company. in a research report on Friday, February 28th. Citigroup lowered their price target on Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a research report on Monday. Hsbc Global Res lowered Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. TD Cowen downgraded Illumina from a "buy" rating to a "hold" rating and decreased their target price for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Finally, Robert W. Baird reduced their price objective on Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a research note on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $138.70.
View Our Latest Analysis on Illumina
Illumina Price Performance
NASDAQ:ILMN traded up $0.81 during trading hours on Friday, hitting $72.07. 866,863 shares of the stock were exchanged, compared to its average volume of 2,252,628. The company has a market cap of $11.42 billion, a P/E ratio of -9.36, a P/E/G ratio of 1.60 and a beta of 1.38. The firm's fifty day moving average price is $89.57 and its 200 day moving average price is $122.68. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63.
Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.
Illumina Company Profile
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Further Reading
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
